Interpace Biosciences

Interpace Biosciences Debt/EBITDA

The Total Debt to EBITDA Ratio of Interpace Biosciences (IDXG) as of Nov 16, 2026 is 0.88. In the previous year, Total Debt to EBITDA Ratio was -4.40 — a change of -120.01% (higher).

Debt/EBITDA

0.88

YoY

-120.01%

Last updated:

Total Debt to EBITDA Ratio of Interpace Biosciences is 2023 0.88 . Total Debt to EBITDA Ratio of Interpace Biosciences was 2022 -4.40 . It decreases by -120.01% higher compared to the previous year.

The Interpace Biosciences Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2015
-0.23 USD
Jan 1, 2016
-5.99 USD
Jan 1, 2017
-2.64 USD
Jan 1, 2019
-0.13 USD
Jan 1, 2020
-0.14 USD
Jan 1, 2021
-0.84 USD
Jan 1, 2022
-4.40 USD
Jan 1, 2023
0.88 USD
The Interpace Biosciences Debt/EBITDA history
YEARDebt/EBITDAYoY
0.88-120.01%
-4.40+425.74%
-0.84+488.02%
-0.14+5.41%
-0.13-94.89%
-2.64-55.86%
-5.99+2,509.85%
-0.23-94.65%
-4.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Interpace Biosciences Stock analysis

What does Interpace Biosciences do? Interpace Biosciences develops and sells diagnostic clinical and pharma services, focusing on molecular tests for cancer risk evaluation. The company offers five commercialized tests: PancraGEN for pancreatic cancer diagnosis from cysts, PanDNA as a molecular snapshot of limited factors, ThyGeNEXT for thyroid cancer diagnosis using sequencing, ThyraMIR v2 used with ThyGeNEXT for thyroid cancer, and RespriDX to differentiate lung cancer origins. These products are sold to healthcare providers and laboratories seeking advanced diagnostic solutions for cancer risk assessment and treatment planning. Interpace Diagnostics, the company's division, provides bioinformatics and pathology services alongside its molecular tests. The tests target specific cancer types, with PancraGEN and PanDNA addressing pancreatic cancer, ThyGeNEXT and ThyraMIR v2 for thyroid cancer, and RespriDX for lung cancer differentiation. Healthcare institutions and physicians utilize these services to improve diagnostic accuracy and patient outcomes in oncology care. The company's revenue streams come from the direct sale of its molecular diagnostic tests and associated services to medical professionals and healthcare facilities. These services are positioned for precision medicine applications, supporting cancer diagnosis, prognosis, and treatment decisions. The business model relies on the clinical utility and technological innovation of its tests to drive adoption among healthcare providers focused on oncology diagnostics. Interpace Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interpace Biosciences stock

Total Debt to EBITDA Ratio of Interpace Biosciences is 0.88 in 2023.

Total Debt to EBITDA Ratio of Interpace Biosciences changed from -4.40 to 0.88, representing a -120.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Interpace Biosciences since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Interpace Biosciences with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Interpace Biosciences

All Key Metrics — Interpace Biosciences